C-myc Expression in Tumor Cells After Cisplatin Treatment
Author Information
Author(s): TL Walker, JD White, WJ Esdale, MA Burton, EE DeCruz
Primary Institution: Biomedical Research Group, School of Science and Technology, Charles Sturt University
Hypothesis
Antisense therapy directed at c-myc in combination with cisplatin may achieve therapeutic efficacies in vivo that greatly exceed those displayed by either agent in isolation.
Conclusion
Cisplatin treatment leads to a significant increase in c-myc expression in surviving tumor cells, which may contribute to chemoresistance.
Supporting Evidence
- Surviving tumor cells showed a significant 2-fold increase in c-myc expression at 48 hours and 7 days after cisplatin treatment.
- Antisense treatment resulted in a 25% growth retardation of tumor cells for up to 4 days.
- Statistical analysis demonstrated a significant difference in tumor growth rates between treated and untreated groups.
Takeaway
When cancer cells are treated with a drug called cisplatin, they start to make more of a protein called c-myc, which helps them survive. This means they might not die like we want them to.
Methodology
The study used a solid transplantable tumor model in rats, treated with a single dose of cisplatin, and analyzed c-myc expression at different time points.
Limitations
The study primarily focuses on a single animal model and may not fully represent human responses.
Participant Demographics
Syngeneic DA rats, 10-16 weeks old.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website